Results 81 to 90 of about 24,005 (199)

Overall survival in the UK in mycosis fungoides or S ´ ezary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care

Journal of Comparative Effectiveness Research, 2023
Aim: Due to extensive treatment switching in the MAVORIC trial, lack of UK regulatory licence for the comparator, overall survival (OS) with mogamulizumab was compared with patients with previously treated advanced mycosis fungoides/S ´ ezary syndrome (
Neil Hawkins, Noemi Muszbek, Rachel Evans, Linda McNamara, Trefor Jones   +4 more
doaj   +1 more source

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy [PDF]

, 2017
Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies. In
Clarke, Kathryn M., Kettyle, Laura M., Mills, Ken I., Thompson, Alexander, Young, Christine S.   +4 more
core   +1 more source

Toward precision oncology: An integrative multi‐omics approach for prognosis prediction and inferred immunotherapy responsiveness in breast cancer

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
We integrated four omics to build a breast cancer immunotherapy predictor. Survival‐associated biomarkers were compressed into 200 latent features via an autoencoder, then refined using three survival models. K‐means defined two subgroups (C1, high‐risk and C2, low‐risk).
Houda Bendani, Nasma Boumajdi, Lahcen Belyamani, Azeddine Ibrahimi   +3 more
wiley   +1 more source

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles

Pharmaceutics, 2018
Suberoylanilide hydroxamic acid (SAHA) or vorinostat (VOR) is a potent inhibitor of class I histone deacetylases (HDACs) that is approved for the treatment of cutaneous T-cell lymphoma.
Anand Kumar Meka, Laura J. Jenkins, Mercedes Dàvalos-Salas, Naisarg Pujara, Kuan Yau Wong, Tushar Kumeria, John M. Mariadason, Amirali Popat   +7 more
doaj   +1 more source

A pharmacogenetic study of vorinostat glucuronidation [PDF]

Pharmacogenetics and Genomics, 2010
High interindividual pharmacokinetic variability was observed in phase 1 studies of vorinostat (suberoylanilide hydroxamic acid), an oral histone deacetylase inhibitor. Thus, we hypothesized that the variability can be explained by genetic variants of the uridine 5'-diphosphate-glucuronosyltransferases (UGTs) involved in vorinostat metabolism ...
Soonmo Peter, Kang, Jacqueline, Ramirez, Larry, House, Wei, Zhang, Snezana, Mirkov, Wanqing, Liu, Eden, Haverfield, Mark J, Ratain   +7 more
openaire   +2 more sources

Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine [PDF]

, 2013
Extent: 11 p.BACKGROUND: Despite the potential of improving the delivery of epigenetic drugs, the subsequent assessment of changes in their epigenetic activity is largely dependent on the availability of a suitable and rapid screening bioassay.
Akkamsetty, Y., Callen, D., Ho, K., Kumar, R., Lim, S., Neilsen, P., Prestidge, C., Suetani, R., Walther, D., Wang, W.   +9 more
core   +2 more sources

DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu, Yuzhu Ma, Yueying Gao, Yao Chen, Xinyu Li, Yue Wu, Meiling Sun, Qizhao Li, Yanhong Zhao, Shuqian Xu, Shengjin Fan, Yongsheng Li, Huitao Fan   +12 more
wiley   +1 more source

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma [PDF]

, 2010
In Burkitt lymphoma/leukemia (BL), achievement of complete remission with first-line chemotherapy remains a challenging issue, as most patients who respond remain disease-free, whereas those refractory have few options of being rescued with salvage ...
Agirre-Ena, X. (Xabier), Beltran, E. (E.), Calasanz-Abinzano, M.J. (Maria Jose), Fresquet, V. (Vicente), Hernandez, J.M. (J. M.), Martinez-Climent, J.A. (José Ángel), Panizo, C. (Carlos), Prosper, F. (Felipe), Richter, J.A. (José Ángel), Richter, J.A. (José Ángel), Robles, E.F. (Eloy Francisco), Roman-Gomez, J. (José), Rullan, A.J. (Antonio J.)   +12 more
core   +1 more source

From Coffee Alkaloid to Ovarian Targets: An Integrated Computational Framework for Trigonelline in Ovarian Aging

Food Science &Nutrition, Volume 14, Issue 2, February 2026.
This study employs an integrative in silico approach combining network pharmacology, molecular docking, and molecular dynamics simulations to explore the molecular association between trigonelline and ovarian aging, identifying five hub proteins (MMP9, JAK2, PARP1, HDAC1, and CYP3A4) and three major mechanistic axes related to extracellular matrix ...
Woon Shin Yong, Yuankun Han, Yulu Shen, Ningyu Sun, Qinhua Zhang   +4 more
wiley   +1 more source

Histone deacetylase inhibitors – molecular mechanisms of actions and clinical applications [PDF]

, 2013
Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression implicated in cancer pathogenesis. Inhibitors of HDACs (HDI) are under investigation as novel anti-cancer drugs, which induce histone hyperacetylation ...
Andrzej Stepulak, Aneta Grabarska, Ewa Nowosadzka, Magdalena Dmoszyńska-Graniczka   +3 more
core   +1 more source